AADR opposes tobacco policy riders in agriculture appropriations bill

The American Association for Dental Research joined with over 50 organizations to oppose tobacco policy riders in the House of Representatives Agriculture Appropriations Bill that would weaken tobacco regulation. Specifically, section 752 of the bill would exempt large and premium cigars from oversight by the Food and Drug Administration (FDA) and could provide a loophole for other tobacco products to escape regulation. Section 753 would exempt tobacco products on the market before a certain date from FDA oversight and weaken the ability of the FDA to remove non-compliant tobacco products from market. Both would weaken the deeming rule that extended the FDA’s regulatory authority to all tobacco products.

During House appropriations committee markup of the bill, an amendment was offered to strike section 753. That amendment was voted down, and the House appropriations bill was approved with the two provisions. The Senate version of the bill, however, does not include either provision.

AADR will continue to track the tobacco policy riders during the appropriations process. Please continue to check the Government Affairs and Science Policy blog for updates.

AADR joins 63 organizations to support CDC OSH

The American Association for Dental Research joined 63 other organizations to support the Centers for Disease Control and Prevention (CDC) Office on Smoking and Health (OSH). In letters sent to both the House and the Senate, health and research organizations requested $210 million in appropriations for CDC OSH, citing the financial and public health burden of tobacco use. The letter also opposed President Trump’s proposal to eliminate the office. From the letters:

OSH plays a critical role in reducing the death and disease caused by tobacco by funding activities that help to prevent youth from starting to use tobacco and help adult tobacco users to quit. For example, OSH funds the highly successful national media campaign, Tips from Former Smokers. This media campaign has motivated about five million smokers to make a quit attempt, helped approximately 500,000 smokers to successfully quit, and saved at least 50,000 people from premature death since its inception in 2012. The campaign is highly cost-effective with a cost of just $393 per year of life saved, far below the $50,000 that is an accepted benchmark for cost-effective public health programs.

AADR will continue to monitor the appropriations process and provide updates as they become available.

House Labor-HHS bill includes $1 billion NIH, $6 million NIDCR increases

The House Appropriations Subcommittee on Labor, Health and Human Services has released its fiscal year 2018 funding bill. The bill includes $35.2 billion for the National Institutes of Health (NIH), an increase of $1.1 billion above the fiscal year 2017 enacted level, and $432 million for the National Institute of Dental and Craniofacial Research (NIDCR), an increase of $6 million over fiscal year 2017.

Subcommittee members articulated support for the NIH during hearings earlier in the summer and indicated that it would reject the $7 billion cut in the President’s fiscal year 2018 budget proposal.

The text of the funding bill can be found here.

Gert Quigley Fellowship Experience

By Tanner Godfrey

For the past six weeks, I have had the opportunity to serve as the Gert Quigley Fellow with the American Association for Dental Research (AADR). This fellowship is designed to give exposure to government affairs and science policy work. It also provides many other opportunities to get to know the organization driving dental research and progress in dentistry. Below I’ve included a summary of the different activities I’ve been involved in through this fellowship:

Government affairs

  • Attended House and Senate appropriations hearings with Dr. France A. Córdova, Director of the National Science Foundation; Dr. Thomas Price, Secretary of Health and Human Services; and Dr. Francis Collin Director of the National Institutes of Health as witnesses.
  • Visited Senators Richard Shelby and Luther Strange of Alabama and discussed our concerns regarding the President’s FY2018 proposed budget.
  • Attended coalition meetings for the Coalition for National Science Funding and the Campaign for Tobacco-Free Kids.

Science Policy

  • Attended National Academy of Sciences workshops on sugar-sweetened beverages and diversity in science.
  • Updated AADR science policy statements

Organization Visits

  • Visited NIH intramural and extramural research campuses and met with Principal Deputy Director of the NIH Dr. Lawrence Tabak; NIDCR Director Dr. Martha Somerman; NIDCR Acting Deputy Director Dr. John Kusiak; and directors of other NIDCR operations including intramural research, extramural research, clinical research, and dental public health residency
  • Visited and toured the American Dental Education Association

Research Project

  • Completed a project analyzing funding sources of AADR members reported on AADR/IADR abstract submissions

These experiences and relationships will prove valuable to me as I seek a career in dental academics. It has also been very fun to be in our nation’s capital and see the many amazing things here! I would highly recommend this experience to those interested in government affairs or science policy, as well as to those interested in a career in dental academics.

Advocating for NIH on Capitol Hill – Update from AADR Gert Quigley Fellow

By Tanner Godfrey

Recently, I had the chance to go and visit the offices of my senators from Alabama, Senators Richard Shelby and Luther Strange. During these meetings, we discussed the President’s proposed budget for the National Institutes of Health (NIH) and accomplishments in research within Alabama. As the President’s budget proposes a cap on indirect costs, we discussed the potential dangers of this proposal to the researchers and universities of Alabama. Both offices were truly splendid and very supportive of our cause to support NIH! Senator Shelby was kind enough to take a picture with me, even though he and his wife had just barely gotten off a plane from France!



NIH director testifies before Senate LHHS

by Tanner Godfrey

During this Senate Labor, Health and Human Services (LHHS) hearing, the focus was on the President’s FY2018 proposed budget cut of $7 billion to the National Institutes of Health (NIH). Recently reappointed director Dr. Francis Collins was the witness. I’ve previously described the commitment of the Senate LHHS subcommittee to preserve funding for NIH, so in this post I want to focus on some key points raised by Dr. Collins. In his testimony, he described three moving examples of the transformational power of investing in NIH basic science.

Cystic Fibrosis – Cryo Electron Microscopy (Cryo-EM), a powerful magnification technique, has enabled the discovery of the precise molecular structure of the protein channel that regulates water and salt balance. This protein is misfolded in cystic fibrosis (CF), our nation’s most common fatal genetic disease. Dr. Collins discovered the genetic mutation, or misspelling, responsible for this disease. Now, structural information is allowing the design of better drugs to treat cystic fibrosis patients like 2-year-old Avalin Mahoney.

“Just a few decades ago she probably wouldn’t have made it beyond her teens; no longer! Today we have two targeted drugs for CF, and more to come, all building on NIH-supported basic research. And we’re not done; the goal is to turn CF into a 100% curable disease,” Dr. Collins said.

Among the next generation of scientists tackling the problem is Dr. Steven Aller from the University of Alabama. He uses computer science and biomedical science to better design targeted drugs for such diseases.

Sickle Cell Disease – Sickle cell is a disease in which red blood cells are sickle shaped due to a genetic misspelling. These misshapen cells can block small arteries. Currently, the only cure for the disease is a bone marrow transplant. However, what of the many patients without a match? That is where current research using CRISPR gene editing by NIH’s Dr. Courtney Fitzhugh comes into play. She is attempting to correct the genetic misspelling associated with sickle cell disease in a patient’s own blood stem cells.

Alzheimer’s Disease – The NIH BRAIN Initiative aims to create a detailed understanding of the 86 billion neurons in the human brain. Using the BRAIN Initiative, scientists hope to identify early warning signs of Alzheimer’s disease, which is estimated to cost $259 billion this year, rising to over $1.1 trillion by 2050. Using advanced warning, effective means of preventing this disease. Current research is tracking a family with inherited Alzheimer’s living in the mountains of Columbia. Using PET scans of the brain they compare those who carry mutations and those who do not in hopes of identifying early warning signs of Alzheimer’s.

Dr. Collins concluded his testimony by telling the senators, “You are all a part of this, your emphasis on Alzheimer’s and related dementias research in fiscal 2016 & 2017 is enabling progress towards our mutual goal of preventing and effectively treating these devastating conditions.”

While taking questions from committee members, Dr. Collins again addressed the issue of capping indirect costs. He said the NIH will look for ways to reduce administrative costs brought on by regulations, but he does not think it will amount to the proposed dramatic rate reduction. Asked about the effect of capping indirect costs at the proposed 10% rate, Dr. Collins replied, “I’m having a hard time imagining how we would manage that.”

LHHS subcommittee shows support for NIH during HHS appropriations hearing

by Tanner Godfrey

The Senate Subcommittee on Labor, Health and Human Services, Education, and Related Agencies met to discuss the 2018 budget recommendations and to question Secretary of Health and Human Services Tom Price. The President’s FY2018 budget proposes deep cuts to the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), Medicare and Medicaid. Senator Roy Blunt of Missouri, who chaired the session, opened by stating that he is committed to not cutting the NIH budget and won’t draft a bill for that cut. Price defended the President’s budget, stating that this was an effort to focus spending on programs that work.

Senator Richard Durbin of Illinois responded by asking, “Do I take it from that that you and the President have concluded that our medical research programs at the NIH have failed the American people?”

Secretary Price attempted to explain that they plan to fund the same number of grants and dollar amount per grant by cutting indirect costs, also called facilities & administration costs, or F&A for short.

This approach, however, also is threatening to scientific research. When a grant is awarded, 67-75% of the grant goes directly to the researcher for the cost of the research (supplies, equipment, salaries, students, etc.). The remaining amount goes to cover the research infrastructure and operating costs (laboratories, waste disposal, patient and animal safety, maintenance, administrative staff, etc.)

A statement from the Association of American Universities on indirect costs said:

Cuts to F&A research costs are cuts to research. If such cuts are made, they will reduce the amount of research universities and their scientists can conduct on behalf of the federal government to achieve key national goals to improve the health and welfare of the American people, grow the economy, and enhance our national security.

Furthermore, according to the congressional justification, NIH predicts with this proposed budget the grant success rate will drop to 13.7%, 1,648 fewer grants will be awarded, and less money will awarded with each grant as well.

The senators present were overwhelmingly supportive of NIH and appeared to be very reluctant to proceed with the President’s budget request. Senator Durbin emphasized, “This chairman along with the ranking member, and I might add Senator [Lamar] Alexander to this combination, have really staked out a grounds in the last two fiscal years that I think is the right path for America. 5% real growth in medical research funding across America, I am ready to debate that in any district, in any state in America; that is money well spent!”

House appropriations committee inquires about proposed NSF cuts

By Tanner Godfrey

The House Committee on Appropriations Science Subcommittee met to discuss the FY18 National Science Foundation (NSF) budget with Director Dr. France A. Córdova as a witness. Dr. Córdova spoke of the advances through NSF funded research touching on topics such as driverless cars, artificial intelligence to predict septic shock, 3D printing organs, and the detection of gravitational waves. The FY18 budget proposes an 11% cut in funding to NSF, the first cut in the organization’s history. If passed, this cut would directly affect the number of new grants awarded by a similar margin. Furthermore, the committee expressed concern for the impacts of decreased funding for cyber security, STEM education and diversity in science.  The representatives present were very supportive of NSF and requested that scientific community speak to their representatives and senators to encourage them to support funding for science. The full video of the hearing as well as Dr. Córdova’s testimony can be found here.

NIH reverses decision on grant cap; creates fund for young investigators

The National Institutes of Health (NIH) has reversed its decision to cap the number of grants that an investigator can receive after pointed opposition from some members of the scientific community and Advisory Committee to the Director. The NIH will instead create a pool of money reserved for early career investigators and mid-career investigators in danger of leaving the research workforce due to lack of funding or who are seeking their second award.

Initially, the NIH created a grant support index (GSI) that assigned a value to each type of research project grant. Under the initial plan, the NIH would essentially limit the number of grants any investigator could hold at once to the equivalent of three single-principle investigator R01s. The NIH estimated that this would create 1,600 new awards that could be more broadly shared among the research workforce. The plan was based on data that showed diminishing returns in productivity after an investigator received a certain number of grants and data that showed the difficulty early and mid-career investigators had in obtaining funding.

The GSI received positive feedback from many members of the scientific community, such as from Future of Research. However, negative feedback to the plan, prompted NIH officials to scrap the GSI and replace it with the Next Generation Research Initiative (NGRI). This new plan will reserve $210 million this year for early and mid-career investigators with the goal of increasing this fund to $1.1 billion dollars per year over 5 years if the budget allows.

The NGRI was announced at the latest meeting of the Advisory Committee to the Director. The NIH is accepting feedback through NIH Deputy Director for Extramural Research, Dr. Mike Lauer’s, blog or at publicinput@od.nih.gov. Information about the new research initiative will be communicated through the NGRI website.

AADR will continue to track developments with this initiative. Please contact Science Policy Analyst, Dr. Seun Ajiboye, at sajiboye@iadr.org with any questions, concerns and feedback.

Collins reappointed as NIH Director

The Trump administration has announced that Dr. Francis Collins will be reappointed as Director of the National Institutes of Health (NIH). Dr. Collins was originally appointed NIH Director by the Obama administration in 2009, having worked on former President Obama’s transition team.

At the end of each administration, political appointees turn in resignation letters to allow the incoming administration to select new personnel. Dr. Collins expected to finish his tenure with the Obama administration but indicated that he wanted to continue as the Director under Trump. Dr. Collins continued to serve on a temporary basis after President Trump took office until a permanent replacement could be named. However, Dr. Collins enjoyed broad support from the research community as well as members of Congress. In an unprecedented step, Republican leaders sent a letter to  President Trump urging him to reappoint Dr. Collins as the head of the NIH. President Trump met with Dr. Collins on many occasions both before and after the President’s inauguration, but Dr. Collins’ future at NIH was unclear until now.

AADR congratulates Dr. Collins on his reappointment and looks forward to continuing to work with the Director and the NIH to support and advance biomedical research.